
    
      A total of 50 patients will be enrolled in this double-blinded, randomized, controlled trial.
      Inclusion criteria: subjects>40 yrs of age with an expected hospital stay in the Medical
      Intensive Care or Regional Heart Unit at LVH Muhlenberg of 6 days or longer (4 days
      bedridden) will be enrolled. Total drug treatment will be 6-14 days while in the hospital. A
      follow up phone call will be performed by the study team approximately 30 days after hospital
      discharge. Primary endpoint: bleeding rate (minor vs major) between study days 1-14.
      Secondary endpoint: DVT study days 1-14 (confirmed with LE duplex ultrasonogram).
    
  